34498 Federal Register / Vol. 65, No. 104 / Tuesday, May 30, 2000 / Notices

Janesville Sts., Village of Oregon,

00000699

Waukesha County

Needham, Enoch Gardner and Mary

Caroline Koch, House, 12713 W.

Greenfield Ave., New Berlin,

00000700

A request for Removal has been made

for the following resources:

Kansas

Kiowa County

Belvidere Medicine River Bridge,

(Masonary Arch Bridges of Kansas

TR) 0.25 mi. N of Belvidere, Belvidere

vicinity, 85001418

Wyandotte County

Huron Building, 905 N. 7th St., Kansas

City, 84001243

[FR Doc. 00–13376 Filed 5–26–00; 8:45 am]

BILLING CODE 4310–70–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on April 21, 2000,

American Radiolabeled Chemical, Inc.,

11624 Bowling Green Drive, St. Louis,

Missouri 63146, made application by

letter to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of gamma

hydroxybutyric acid (2010), a basic class

of controlled substance listed in

Schedule I.

The firm plans to bulk manufacture

small quantities of the listed controlled

substance as radiolabeled compound.

Any other such applicant and any

person who is prsently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 31,

2000.

Dated: May 19, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–13439 Filed 5–26–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated February 10, 2000,

and published in the Federal Register

on February 17, 2000, (65 FR 8206),

Ansys Diagnostics, Inc., 25200

Commercentre Drive, Lake Forest,

California 92630, made application by

renewal to the Drug Enforcement

Administration (DEA) to be registered as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Phencyclidine (7471) .................... II

1–Piperid-ino-cyclo-hex-anecarbo-nitrile (PCC) (8603).II

Benzoylecgonine (9180) ............... II

The firm plans to manufacture the

listed controlled substances to produce

standards and controls for in-vitro

diagnostic drug testing systems.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Ansys Diagnostics, Inc. to

manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated Ansys Diagnostics, Inc. on

a regular basis to ensure that the

company’s continued registration is

consistent with the public interest.

These investigations have included

inspection and testing of the company’s

physical security systems, audits of the

company’s records, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby order that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic classes of controlled

substances listed above is granted.

Dated: May 19, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–13437 Filed 5–26–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on February 29, 2000,

Chemic Laboratories, Inc., 480 Neponset

Street, Building 7C, Canton,

Massachusetts 02021, made application

to the Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of cocaine (9041), a basic

class of controlled substance listed in

Schedule II.

The firm plans to bulk manufacture

small quantities of cocaine derivative

for a customer.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 31,

2000.

Dated: May 19, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–13438 Filed 5–26–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated February 10, 2000,

and published in the Federal Register

on February 17, 2000, (65 FR 8207),

Noramco of Delaware, Inc., Division of

McNeilab, Inc., which has changed its

name to Noramco of Delaware, Inc.,

Division of Ortho-McNeil, Inc., 500 Old

Swedes Landing Road, Wilmington,

Delaware 19801, made application by

renewal to the Drug Enforcement

Administration (DEA) to be registered as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Codeine (9050) ............................. II

Oxycodone (9143) ........................ II

Federal Register / Vol. 65, No. 104 / Tuesday, May 30, 2000 / Notices 34499

Drug Schedule

Hydrocodone (9193) ..................... II

Morphone (9300) .......................... II

Thebaine (9333) ........................... II

The firm plans to manufacture the

listed controlled substances for

distribution to its customers as bulk

product.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Noramco of Delaware,

Inc. to manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated Noramco of Delaware, Inc.

on a regular basis to ensure that the

company’s continued registsration is

consistent with the public interest.

These investigations have included

inspection and testing of the company’s

physical security systems, audits of the

company’s records, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic classes of

controlled substances listed above is

granted.

Dated: May 19, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–13435 Filed 5–26–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated February 10, 2000,

and published in the Federal Register

on February 17, 2000, (65 FR 8207),

Orpharm, Inc., 4815 Dacoma, Houston,

Texas 77092, made application by

renewal to the Drug Enforcement

Administration (DEA) to be registered as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Methadone (9250) ........................ II

Methadone-intermediate (9254) ... II

levo-alphacetymethadol (9648) .... II

The firm plans to manufacture

methadone and methadone-intermediate

for production of LAAM.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Orpharm, Inc. to

manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated Orpharm, Inc. on a regular

basis to ensure that the company’s

continued registration is consistent with

the public interest. These investigations

have included inspection and testing of

the company’s physical security

systems, audits of the company’s

records, verification of the company’s

compliance with state and local laws,

and a review of the company’s

background and history. Therefore,

pursuant to 21 U.S.C. § 823 and 28 CFR

0.100 and 0.104, the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic classes of controlled

substances listed above is granted.

Dated: May 19, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–13436 Filed 5–26–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Federal Bureau of Investigation

Agency Information Collection

Activities: Current Collection:

Comments Requested

ACTION: Notice of information collection

under review: extension of a currently

approved collection; Return A—

Monthly Return of Offenses Known to

the Police and Supplement to Return

A—Monthly Offenses Known to the

Police

The proposed information collection

is published to obtain comments from

the public and affected agencies.

Comments are encouraged and will be

accepted until July 31 2000.

Request written comments and

suggestions from the public and affected

agencies concerning the proposed

collection of information. Comments

should address one or more of the

following four points:

(1) Evaluate whether the proposed

collection of information is necessary

for the proper performance of the

functions of the agency, including

whether the information will have

practical utility;

(2) Evaluate the accuracy of the

agencies estimate of the burden of the

proposal collection of information,

including the validity of the

methodology and assumptions used;

(3) Enhance the quality, utility, and

clarity of the information to be

collected; and

(4) Minimize the burden of the

collection of information on those who

are to respond, including through the

use of appropriate automated,

electronic, mechanical, or technological

collection techniques of other forms of

information technology, e.g., permitting

electronic submission of responses.

Comments and/or suggestions

regarding the item(s) contained in this

notice, especially regarding the

estimated public burden and associated

response time should be directed to

Gregory E. Scarbro (phone number and

address listed below). Additional

information as well as copies of the

proposed information collection

instrument with instructions are

available by contacting Gregory E.

Scarbro, Unit Chief, telephone 304–625–

4830, FBI, CJIS Division, Statistical

Unit, E–3, 1000 Custer Hollow Road,

Clarksburg, WV 26306.

Overview of This Information

Collection

(1) Type of information collection:

Extension of Currently Approved

Collection.

(2) The title of the form/collection:

Return A—Monthly Return of Offenses

Known to the Police and Supplement to

Return A—Monthly Offenses Known to

the Police.

(3) The agency form number, if any,

and applicable component of the

Department Sponsoring the collection.

Form: 1–720A; 1–706. Federal Bureau of

Investigation, Department of Justice.

(4) Affected public who will be asked

or required to respond, as well as brief

abstract. Primary: Local and State Law

Enforcement Agencies. This collection

is needed to collect data regarding

criminal offenses and their respective

clearances throughout the United States.

Data is tabulated and published in the

annual Crime in the United States. The

FBI UCR Program is currently reviewing

its race and ethnicity data collection in

compliance with the Office of

Management and Budget’s Revisions for

the Standards for the Classification of

Federal Data on Race and Ethnicity.

(5) An estimate of the total number of

respondents and the amount of time

estimated for an average respondent to

respond: 17,667 agencies with 212,004

responses (including zero reports); and